Source: ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Katrine Prætorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen, Bo L. Chawes. Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma. ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021

Member's Comments

No comment yet.

Related content which might interest you: Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Efficacy and safety of long-term therapy with Salamol combined with Beclason versus Salamol only in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2 Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Comparative effectiveness of add-on omalizumab for the treatment of severe persistent asthma between current and former smokers vs. non-smokers Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo Source: International Congress 2017 – Asthma management Year: 2017 Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001 Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007